Work

Comparison of interpatient and intrapatient variability in doxorubicin exposure using a validated limited sampling model in dogs with cancer

Year: 2025

Type: article

Abstract: Background: Doxorubicin (DOX) is an anthracycline chemotherapeutic used for many canine malignancies, and its adverse event (AE) profile has been well-described in dogs. A limited sampling (LS) pharmacokinetic model was recently developed in canine patients to predict hematologic exposure to DOX. The primary goal of this study was to evaluate within-patient and between-patient variability in DOX exposure over three consecutive doses using the LS model. A secondary goal was to determine if there is a correlation between DOX exposure and gastrointestinal (GI) AEs utilizing a standardized owner questionnaire. Methods: We performed a prospective evaluation of DOX exposure in seven tumor-bearing dogs across three cycles of treatment and compared the coefficient of variation (%CV) of the between- and within-patient exposures. Results: = 0.02) were significantly correlated with DOX exposure. Conclusions: Together, these data suggest wide interpatient variability in dose-normalized DOX exposure but much more consistent exposure within an individual patient across treatment cycles. Future studies can attempt to target specific DOX exposures and absolute neutrophil counts to assess if DOX dosing can be personalized to increase efficacy and decrease GI AEs. Supplementary Information: The online version contains supplementary material available at 10.1186/s44356-025-00038-z.

Source: Veterinary oncology.

DOI: 10.1186/s44356-025-00038-z

Authors: Sridhar Madan Veluvolu, Robert B. Rebhun, Jaeyoung Kim, Luke Anthony Wittenburg

Institutions: University of California, Davis, UC Davis Comprehensive Cancer Center

Language: English

Topic: Veterinary Oncology Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,490